InnoCare Pharma Limited (OTCMKTS:INCPF) Short Interest Update

Posted by Brian Himes on Aug 29th, 2026

InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 124,000 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of InnoCare Pharma to an “overweight” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy”.

View Our Latest Research Report on InnoCare Pharma

InnoCare Pharma Stock Performance

INCPF stock remained flat at $1.55 during midday trading on Friday. InnoCare Pharma has a 1-year low of $1.55 and a 1-year high of $2.31. The firm has a fifty day simple moving average of $1.55 and a two-hundred day simple moving average of $1.58.

InnoCare Pharma Company Profile

(Get Free Report)

InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.

The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.